$7.52
+0.02 (+0.27%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ACHV is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
31 interventional · 10 with posted results
Held by 7 tracked-famous managers (MARSHALL WACE, LLP, TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, +2 more) · FINRA short interest 15.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E CigarettesNCT07392125Primary Efficacy ObjectiveRandomized · Quadruple-masked · Treatment | Phase 3 | Not yet recruiting | Drug: Cytisinicline, Placebo · Behavioral: Behavioral Support | Vaping Cessation | 800 | 2026-11-15 | in 88 d | 2026-02-06 |
| Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette SmokersNCT06435221Incidence Rate of Treatment Emergent Serious Adverse Events (SAEs)Open-label · Treatment | Phase 3 | Completed | Drug: Cytisinicline | Smoking Cessation, Vaping Cessation | 479 | 2025-09-29actual | — | 2025-11-26 |
| Study to Evaluate Effect of Food on Bioavailability of Single 3 mg Tablet and Pharmacokinetics (PK) of Multiple 3 mg Doses in Healthy Adult SmokersNCT05981768Maximum Observed Plasma Concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Cytisinicline | Smoking Cessation | 30 | 2023-09-21actual | — | 2023-10-18 |
| Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline DoseNCT05631938Plasma Pharmacokinetic (PK) Parameter: Maximum Observed Plasma Concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: cytisinicline | Renal Impairment | 44 | 2023-09-04actual | — | 2025-07-11 |
| A Second Study of Cytisinicline for Smoking Cessation in Adult SmokersNCT05206370results2026-01-14Percentage of Participants With Smoking Abstinence From Weeks 3 to Week 6Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Cytisinicline, Placebo · Behavioral: Behavioral support | Smoking Cessation | 792 | 2023-03-21actual | — | 2026-01-14 |
| A Study of Cytisinicline for Vaping Cessation in Adult SmokersNCT05431387results2026-01-14Percentage of Participants With Vaping Abstinence From Week 9 to 12Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: cytisinicline, Placebo · Behavioral: Behavioral support | Vaping, E-Cig Use | 160 | 2023-02-28actual | — | 2026-01-14 |
| Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy SmokersNCT05566288Predicted Placebo-Adjusted Change From Baseline in the Corrected QT Interval using Fridericia's Formula (QTcF) Interval (ΔΔQTcF)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: Cytisinicline, Placebo, Moxifloxacin | Smoking Cessation | 27 | 2022-12-23actual | — | 2023-05-18 |
| A Study of Cytisinicline for Smoking Cessation in Adult SmokersNCT04576949results2024-11-14Percentage of Participants With Smoking Abstinence From Weeks 3 to Week 6Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Cytisinicline, Placebo · Behavioral: Behavioral support | Smoking Cessation | 810 | 2021-12-23actual | — | 2026-01-15 |
| A Single Dose-escalation Study of Cytisine in Adult SmokersNCT03848208results2020-09-17Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Study DiscontinuationRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: cytisine, placebo | Smoking Cessation | 74 | 2019-09-12actual | — | 2020-09-17 |
| Trial of Cytisine in Adult SmokersNCT03709823results2020-05-18Primary Efficacy Analysis of Primary Outcome Measure: Percentage of Expected Cigarettes Smoked Per Participant During Study TreatmentRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Cytisine, Placebo Comparator · Behavioral: Behavioral support | Smoking Cessation | 254 | 2019-04-23actual | — | 2020-05-18 |
| A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy SmokersNCT03303911results2019-10-21Maximum Observed Plasma Concentration (Cmax)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: It has been difficult to recruit participants meeting study entry criteria that are \>65 years of age and not for any safety reasons. | Drug: Cytisine | Smoking Cessation | 26 | 2018-10-05actual | — | 2019-10-21 |
| A Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New FormulationNCT03509948results2019-09-12Maximum Concentration (Cmax)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: cytisine | Smoking Cessation | 13 | 2018-06-10actual | — | 2019-09-24 |
| A Study in Healthy Volunteers to Investigate the Effect of Food on the Bioavailability of CytisineNCT03268343results2019-02-07Plasma Cytisine Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Cytisine | Smoking Cessation | 24 | 2017-08-26actual | — | 2019-02-26 |
| A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung CancerNCT01630733Overall Survival: All Randomized PopulationRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Custirsen, Docetaxel | Non-Small Cell Lung Cancer | 664 | 2016-11-17actual | — | 2026-04-15 |
| Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate CancerNCT01578655Survival in the intent-to-treat populationRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: cabazitaxel, prednisone, custirsen sodium | Prostate Cancer | 630 | Jul 2016actual | — | 2016-10-12 |
| A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder CancerNCT01454089Overall Survival (OS)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: OGX-427 600 mg, OGX-427 1000 mg, Placebo, Gemcitabine, Cisplatin, Carboplatin | Urologic Neoplasms, Metastatic Bladder Cancer, Urinary Tract Neoplasms | 183 | Nov 2014actual | — | 2016-10-07 |
| Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate CancerNCT01188187Kaplan-Meier Estimates for Time to Death (Overall Survival)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Custirsen, Docetaxel, Prednisone, Dexamethasone | Prostate Cancer | 1,022 | Feb 2014actual | — | 2016-10-14 |
| Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac RepolarizationNCT01874561Individually-corrected QT interval (QTcI)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Custirsen, Placebo, Moxifloxacin | Cardiac Conduction and Repolarization | 155 | Dec 2013actual | — | 2016-10-10 |
| A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment RegimenNCT01497470To evaluate the impact of custirsen on paclitaxel pharmacokineticsOpen-label | Phase 1 | Completed | Drug: Custirsen, paclitaxel and carboplatin | Cancer | 36 | Jul 2013actual | — | 2016-10-10 |
| A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)NCT01083615To ascertain whether the investigational arm has a greater proportion of patients with durable pain palliation as compared to the control arm.Randomized · Quadruple-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Unable to enroll due to criteria for stable baseline pain | Drug: custirsen sodium, isotonic, 0.9% sodium chloride, docetaxel, cabazitaxel, prednisone | Castrate-Resistant Prostate Cancer, Hormone Refractory Prostate Cancer | 14 | Mar 2013actual | — | 2016-10-12 |
| Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder CancerNCT00487786• To determine the maximum tolerated dose (MTD) of OGX-427 when administered as a single agent, up to a 1000 mg dose level.Open-label · Treatment | Phase 1 | Completed | Drug: OGX-427, Docetaxel | Neoplasms | 64 | Jun 2011actual | — | 2016-01-18 |
| Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPCNCT00327340results2012-08-29Safety and Tolerability of Custirsen (OGX-011) in Combination With Either Docetaxel/Prednisone or Mitoxantrone/Prednisone as Second-line Chemotherapy.Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: custirsen (OGX-011)/mitoxantrone, custirsen (OGX-011)/docetaxel | Prostate Cancer | 70 | Oct 2010actual | — | 2012-10-05 |
| A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)NCT00138658results2012-01-10Objective Response Rate of OGX-011 in Combination With Gemcitabine/Platinum-based RegimenOpen-label · Treatment | Phase 1/2 | Completed | Drug: custirsen sodium | Non-small Cell Lung Cancer | 85 | Mar 2010actual | — | 2012-02-06 |
| Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid TumorsNCT00385177Maximum Tolerated DoseNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: SN2310 Injectable Emulsion | Breast Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Pelvic Neoplasms, Lung Neoplasms | 61 | Dec 2008actual | — | 2009-06-04 |
| Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian CancerNCT00034151Determine the objective and partial response ratesNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: S-8184 Paclitaxel Injectable Emulsion | Ovarian Cancer | 52 | Sep 2007actual | — | 2009-06-04 |
| Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung CancerNCT00034164To determine the objective response rateNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: S-8184 Paclitaxel Injectable Emulsion | Carcinoma, Non-Small-Cell Lung | 52 | Sep 2007actual | — | 2009-06-04 |
| Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the UrotheliumNCT00034177Objective response rate; time to disease progression; duration of response; survival; toxicitiesNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: S-8184 Paclitaxel Injectable Emulsion, Experimental Arm: TOCOSOL Paclitaxel | Urologic Neoplasms | 27 | Sep 2007actual | — | 2009-06-04 |
| Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal AdenocarcinomaNCT00034190Determine the Objective Response RateNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: S-8184 Paclitaxel Injectable Emulsion | Colorectal Adenocarcinoma | 28 | Sep 2007actual | — | 2009-06-04 |
| Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast CancerNCT00096668TolerabilityNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: TOCOSOL(R) Paclitaxel | Breast Cancer | 47 | Sep 2007actual | — | 2009-06-04 |
| Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast CancerNCT00251095Objective response ratesRandomized · Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: Failed primary endpoint | Drug: Taxol, TOCOSOL Paclitaxel | Breast Neoplasm | 821 | Sep 2007actual | — | 2009-06-04 |
| TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the UrotheliumNCT00077688Objective response rateNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: TOCOSOL Paclitaxel | Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Carcinoma, Transitional Cell | 44 | — | — | 2009-06-04 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19